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of population, economic & ﬁ nancial information, organization, prescription pattern 
and patient management. We ﬁ rst ran a principal component analysis on quantitative 
variables and then a multiple correspondence analysis on qualitative variables, in order 
to get individuals coordinates of PCTs on several axes on which they were projected. 
We then merged the results, and ran an analysis to create PCTs clusters. RESULTS: 
We identiﬁ ed 5 clusters of PCTs with differentiated, homogeneous attitude towards 
innovative drugs. Cluster 1 focused on MH disorders with GP-level decision-making, 
cluster 2 focused on MH disorders and contained high-prescribing physicians, cluster 
3 had low recognition of MH disorders, cluster 4 had low recognition but offered a 
high level of care while cluster 5 was focused on cost containment. The clusters also 
varied in population size from 1.2 M to 23.9 M. CONCLUSIONS: As this work was 
rather innovative it was validated by local pharmaceutical sales and marketing orga-
nization. The cluster approach proposed was endorsed by account managers’ prag-
matic experience in the ﬁ eld and correlated well with their experience of obtaining 
access for their innovative MH drugs. This study helped to improve our understanding 
of the UK landscape in patient access for innovative drugs in MH.
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OBJECTIVES: Attention-Deﬁ cit/Hyperactivity Disorder (ADHD) is a neurobehavioral 
developmental disorder, that is characterized by hyperactivity and impulse control 
disorder. In Germany pharmaceutical therapy is approved for children and adolescents 
solely. Therefore, treating adult patients with ADHD complies with off-label use of 
stimulants. Aim of this Health Technology Assessment is to examine the clinical 
effectiveness, cost-effectiveness, ethical-social and legal aspects of pharmacotherapy 
(stimulants, antidepressants, norepinephrine reputake inhibitors) of adult ADHD 
patients. METHODS: A systematic literature research is conducted in relevant elec-
tronic literature databases. Studies matching the ex ante deﬁ ned inclusion criteria are 
assessed systematically and qualitatively according to methodical standards by two 
reviewers. Due to heterogeneity of included studies no meta-analysis is performed. 
RESULTS: Nine randomised controlled trials (RCT), ﬁ ve systematic reviews, three 
economic and two studies concerning legal aspects are included. All RCT show 
improvement regarding ADHD symptoms (hyperactivity, impulsivity). Response rates 
vary between 7 % and 42 % in the control group and 17 % to 59,6 % in the inter-
vention group. The studies use primarily investigator and self-rated questionnaires 
such as the ADHD Rating Scale, the Conners Scales and the Clinical Global Impression 
as outcome parameters for the core symptoms of ADHD. Some studies show a larger 
improvement of the ADHD symptoms by a ﬂ exible dose approach. The systematic 
reviews demonstrate statistically signiﬁ cant improvement in symptoms of ADHD 
compared to placebo and other medications. The effect sizes for stimulants are some-
what higher than for non-stimulants. Adult ADHD patients cause higher annual direct 
and indirect costs than matched controls. The average medical costs are reported with 
1.262 US-Dollar in 1998 and 1.673 US-Dollar in 2001. CONCLUSIONS: Method-
ological limitations of the RCT are the short study duration and the high drop-out 
rates. Further research is needed to determine the cost-effectiveness of medical treat-
ment of adult ADHD patients.
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OBJECTIVES: To determine the prevalence of affective disorders (section F3 in 
ICD-10) in South-West region of Sweden. METHODS: This was a retrospective 
longitudinal descriptive database study of the utilization of health care of patients 
from the South-West region of Sweden (1.5 million inhabitants). All patients who were 
diagnosed with affective disorders between 2001 and 2007 in the South-West region 
of Sweden were included in the study. The patients were diagnosed in primary-, in- and 
out-patient care. RESULTS: A total of 138,194 patients were diagnosed with at least 
one type of affective disorder. This corresponded to a prevalence of 9% in the popula-
tion of South-West region in Sweden. 89 percent (123,524 patients) of the total sample 
were diagnosed with major depressive disorder (F32) followed by recurrent depressive 
disorder (F33) at 14% (19,944 patients). Bipolar affective disorder (F31) was diag-
nosed in 5% of the patients (6932) and unspeciﬁ ed mood (affective) disorder (F39) 
was diagnosed in 4% of the patients (5,431). The prevalence of the different diagnoses 
were 8 percent for depressive episode, 1 percent for recurrent depressive disorder, 0.5 
percent for bipolar affective disorder, 0.4% for unspeciﬁ ed mood (affective) disorder. 
CONCLUSIONS: Depressive episode was by far the most common of the affective 
disorders diagnosed, with a prevalence of 8 percent. a question remains whether the 
prevalence for bipolar is underestimated as this study found it to be 0.5%. The 
expected prevalence for bipolar disorder is 1 percent of the population. One plausible 
explanation could be that bipolar patients are classiﬁ ed with other codes than F31 in 
the South-West region of Sweden.
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OBJECTIVES: Despite the use of antipsychotics to treat dementia patients, the efﬁ cacy 
of the treatment is not well established. We examine factors associated with antipsy-
chotics use among community-dwelling older persons with dementia. METHODS: 
We used data from The Aging, Demographics, and Memory Study (ADAMS) to assess 
dementia severity and service use from 2002 to 2004. We used logistic regressions to 
identify factors associated with antipsychotic use; N = 307. RESULTS: Among older 
persons with dementia living in community (weighted sample = 207,544), 7.8% 
(weighted sample = 16,272) took any antipsychotic medications; 69.1% were female, 
70.7% were white, and 21.8% were African American. The average age was 85 years. 
Physical functions were measured by the number of ADL (average. 2.9) and number 
of IADL (mean 3.6). The most frequent primary diagnoses were Alzheimer’s disease 
(74.3%), vascular dementia (16.0%) and other dementia (9.8%).The most frequently 
prescribed antipsychotics were: risperidone (58.0%), quetiapine (15.4%), and halo-
peridol (7.7%). Of those taking an antipsychotic, 86.0% were diagnosed with 
Alzheimer’s dementia. We used the Neuropsychiatry Inventory (NPI) for behavior 
problems (delusions, hallucinations, agitation/aggression, depression, apathy, elation, 
anxiety, disinhibition, irritability/lability, and aberrant motor behavior). We evaluated 
severity of dementia using the Clinical Dementia Rating Scale (CDR).Community-
dwelling older persons with dementia are signiﬁ cantly more likely to receive antipsy-
chotics if they were agitated (OR = 3.4, P < 0.05), had disinhibition (OR = 4.6, P < 
0.05), or had greater dementia severity (OR = 1.9, P < 0.01). Also, Medicaid recipients 
were signiﬁ cantly more likely to receive antipsychotic medications (OR = 5.4, P < 
0.01). Participants were signiﬁ cantly less likely to be medicated with antipsychotics if 
they had vascular dementia (OR = 0.09, P < 0.05) or the caregivers were clinically 
depressed (OR = 0.2, P < 0.05). CONCLUSIONS: Community-dwelling older persons 
with dementia are more likely to receive antipsychotics if caregivers report behavior 
problems, the dementia is more advanced, and the patient has Medicaid coverage. 
Persons with vascular dementia are less likely to be treated with antipsychotics.
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OBJECTIVES: Treatment discontinuation in psychiatric care is a major cause for the 
deterioration of mental health problems. This study assessed reasons for treatment 
discontinuation of patients suffering from schizophrenia or depression in a local 
mental health care system in Germany. METHODS: A retrospective survey was per-
formed to assess how coordination of care through mental health care providers in 
the Rhein-Kreis-Neuss region (Germany) is organized. Within this survey reasons for 
treatment discontinuation were explored from the perspective of providers and 
patients. 88 providers of care (60 institutions) and 30 patients diagnosed with schizo-
phrenia and 17 patients diagnosed with major depression were interviewed using in-
depth face-to-face interviews. Additionally providers were qualitatively interviewed 
on strategies to prevent discontinuations. RESULTS: Providers were asked to rank 
pre-speciﬁ ed reasons for treatment discontinuation according to their occurrence 
(often, occasionally, seldom, never). 38.8 % ranked non-adherence to medication as 
often, 38.1 % waiting times for next treatment. 25.6 % identiﬁ ed problems in the 
patient’s social environment as being often a reason for treatment discontinuation, 
23.7 % mentioned revolving doors effects, 19.3 % resistance to therapy and 12.3 % 
lack of communication between providers. Patients diagnosed with schizophrenia 
(mean age 45 years; mean duration of illness 16 years) and depression (mean age 45 
years; mean duration of illness 13 years) indicated that they consider discontinuation 
or actually discontinue treatment when there is a lack of social integration or when 
there is no reaction of providers to articulated problems with treatments. In response 
to an open question on suggestions for improvement, providers recommended better 
cross-sectoral coordination, earlier start of treatment and early return to normal daily 
living as appropriate measures. CONCLUSIONS: From the subjective perspective of 
providers and patients a variety of causes seem to inﬂ uence treatment discontinuation. 
More research into speciﬁ c interventions to improve treatment adherence is needed.
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OBJECTIVES: To assess if patients suffering from schizophrenia or depression are 
affected by waiting times for the next treatment in a mental health care system in 
Germany. METHODS: Aa retrospective survey was performed to assess coordination 
of care through providers engaged in the care for patients with schizophrenia or major 
depression in the Rhein-Kreis-Neuss region (Germany). One parameter for evaluating 
quality of coordination is the occurrence of waiting times, emerging when patients are 
